Lassa fever (LF), a severe hemorrhagic illness, is one of the most threatening infectious diseases known because of its unique status as both an immediate public health crisis and a bio-safety level 4 (BL-4) potential bioterror hazard. Endemic in large parts of West Africa, LF is estimated to hospitalize tens of thousands of individuals and cause several thousand deaths each year, with a case fatality rate in hospitalized patients that can reach 50% or more. Antibody-based surveys suggest that infection with the LF-causing agent, Lassa virus (LASV), is far more widespread than previously thought, with over 20% of Nigerians and Sierra Leoneans showing evidence of exposure. It is not known why many West Africans infected with LASV do not exhibit disease symptoms while others go on to suffer encephalitis, deafness and death, but recent genomic studies offer a hypothesis. A genome-wide survey of human genetic variation identified two genes biologically linked to LF infection among the strongest signals of recent human adaptation in West Africans. Further analysis of the LASV genome itself indicates that the virus has been circulating in West Africa for over a millennium. These findings-coupled with the high rates of disease, observed disease resistance, significant mortality and disability in affected individuals, and the widespread exposure to the rodent reservoir for the virus-suggest that LF is an ancient selective force, driving the emergence of genetic variants that confer resistance. LASV's unique status among BL-4 agents as a widespread, long-standing selective force is reflected in the serious global health risk it poses, but also provides a tremendous opportunity to study LF and the genetic mechanisms of resistance to it. Along with our partners in the US and Africa, we have built thriving clinical and research centers in Nigeria and Sierra Leone, and implemented diagnostics, training and infrastructure there to ensure safe, high-quality sample collection from patients hospitalized with LF. We have performed a preliminary genome scan and found several promising candidate adaptive and immune genetic variants associated with LF resistance. We have further developed a number of high-throughput technological approaches to rapidly validate and characterize these variants functionally. Based on our previous success in this area, we propose to pursue genetic determinants of resistance to LF through a larger patient collection, deeper diagnostic characterization, more extensive genetic studies, and functional characterization of candidate variants. Through our study, we hope to lay a foundation for the development of vaccines and diagnostics while also providing a path forward for further research into LASV and other BL-4 agents.

Public Health Relevance

Lassa fever, a severe hemorrhagic illness endemic in West Africa, poses perhaps the greatest potential threat among all infectious diseases due to its unique status as both an immediate public health crisis and a Biosafety Level 4 potential bioterror threat. Recent findings from genome scans suggest that Lassa fever is an ancient disease that over time has driven genetic variants conferring disease resistance to high prevalence in affected populations. We aim to identify and elucidate genetic factors in humans that underlie the wide variation in disease resistance, to provide insight into viral pathogenesis and potentially lead to new methods of intervention.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Genetics of Health and Disease Study Section (GHD)
Program Officer
Repik, Patricia M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Broad Institute, Inc.
United States
Zip Code
Siddle, Katherine J; Eromon, Philomena; Barnes, Kayla G et al. (2018) Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018. N Engl J Med 379:1745-1753
Okokhere, Peter; Colubri, Andres; Azubike, Chukwuemeka et al. (2018) Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infect Dis 18:684-695
Dudas, Gytis; Carvalho, Luiz Max; Bedford, Trevor et al. (2017) Virus genomes reveal factors that spread and sustained the Ebola epidemic. Nature 544:309-315
Colubri, Andres; Silver, Tom; Fradet, Terrence et al. (2016) Transforming Clinical Data into Actionable Prognosis Models: Machine-Learning Framework and Field-Deployable App to Predict Outcome of Ebola Patients. PLoS Negl Trop Dis 10:e0004549
Wohl, Shirlee; Schaffner, Stephen F; Sabeti, Pardis C (2016) Genomic Analysis of Viral Outbreaks. Annu Rev Virol 3:173-195
Tewhey, Ryan; Kotliar, Dylan; Park, Daniel S et al. (2016) Direct Identification of Hundreds of Expression-Modulating Variants using a Multiplexed Reporter Assay. Cell 165:1519-1529
Yozwiak, Nathan L; Happi, Christian T; Grant, Donald S et al. (2016) Roots, Not Parachutes: Research Collaborations Combat Outbreaks. Cell 166:5-8
Andersen, Kristian G; Shapiro, B Jesse; Matranga, Christian B et al. (2015) Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell 162:738-50